Y-mabs Therapeutics logo

Y-mabs Therapeutics Share Price Today

(NASDAQ: YMAB)

Y-mabs Therapeutics share price is $4.85 & ₹421.80 as on 6 Mar 2025, 2.30 'hrs' IST

$4.85

-0.11

(-2.22%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Y-mabs Therapeutics share price in Dollar and Rupees. Guide to invest in Y-mabs Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Y-mabs Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Y-mabs Therapeutics share price movements

  • Today's Low: $4.57
    Today's High: $4.98

    Day's Volatility :8.23%

  • 52 Weeks Low: $4.85
    52 Weeks High: $18.19

    52 Weeks Volatility :73.33%

Y-mabs Therapeutics (YMAB) Returns

PeriodY-mabs Therapeutics Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-51.84%
2.1%
0.0%
6 Months
-64.55%
-4.1%
0.0%
1 Year
-72.43%
2.2%
0.0%
3 Years
-40.31%
11.8%
-11.6%

Y-mabs Therapeutics (YMAB) Key Statistics

in dollars & INR

Previous Close
$4.96
Open
$4.85
Today's High
$4.98
Today's Low
$4.57
Market Capitalization
$232.5M
Today's Volume
$216.0K
52 Week High
$18.1869
52 Week Low
$4.57
Revenue TTM
$84.6M
EBITDA
$-23.4M
Earnings Per Share (EPS)
$-0.54
Profit Margin
-28.22%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-24.78%

How to invest in Y-mabs Therapeutics Stock (YMAB) from India?

It is very easy for Indian residents to invest directly in Y-mabs Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Y-mabs Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Y-mabs Therapeutics or YMAB on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Y-mabs Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Y-mabs Therapeutics shares which would translate to 0.179 fractional shares of Y-mabs Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Y-mabs Therapeutics, in just a few clicks!

Returns in Y-mabs Therapeutics (YMAB) for Indian investors in Rupees

The Y-mabs Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Y-mabs Therapeutics investment value today

Current value as on today

₹31,922

Returns

₹68,078

(-68.08%)

Returns from Y-mabs Therapeutics Stock

₹73,041 (-73.04%)

Dollar Returns

₹4,963 (+4.96%)

Indian investors sentiment towards Y-mabs Therapeutics (YMAB)

275%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Y-mabs Therapeutics Stock from India on INDmoney has increased by 275% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Y-mabs Therapeutics

  • Paradigm Biocapital Advisors LP

    9.46%

  • BlackRock Inc

    6.69%

  • Sofinnova Ventures

    4.90%

  • Vanguard Group Inc

    4.47%

  • Polar Capital Holdings PLC

    4.09%

  • Caligan Partners LP

    3.95%

Analyst Recommendation on Y-mabs Therapeutics

Buy

    76%Buy

    15%Hold

    7%Sell

Based on 13 Wall street analysts offering stock ratings for Y-mabs Therapeutics(by analysts ranked 0 to 5 stars)

Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
2
2
2
Sell
1
1
1

Analyst Forecast on Y-mabs Therapeutics Stock (YMAB)

What analysts predicted

Upside of 319.87%

Target:

$20.36

Current:

$4.85

Insights on Y-mabs Therapeutics Stock (Ticker Symbol: YMAB)

  • Price Movement

    In the last 3 months, YMAB stock has moved down by -51.8%
  • Increasing Revenue

    Revenue is up for the last 2 quarters, 18.46M → 26.49M (in $), with an average increase of 30.3% per quarter
  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -9.24M → -6.79M (in $), with an average increase of 17.6% per quarter
  • YMAB vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 62.3% return, outperforming this stock by 132.5%
  • YMAB vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 47.7% return, outperforming this stock by 86.3%
  • Price to Sales

    ForYMAB every $1 of sales, investors are willing to pay $2.6, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $13.8 for every $1 of sales.

Y-mabs Therapeutics Technicals Summary

Sell

Neutral

Buy

Y-mabs Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Y-mabs Therapeutics (YMAB) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Y-mabs Therapeutics Inc. logo
-17.33%
-64.55%
-72.43%
-40.31%
-80.02%
Regeneron Pharmaceuticals, Inc. logo
1.3%
-41.29%
-30.51%
9.2%
42.38%
Beone Medicines Ltd logo
15.19%
34.31%
61.3%
43.16%
68.1%
Vertex Pharmaceuticals Incorporated logo
3.37%
3.77%
18.06%
106.43%
121.36%
Alnylam Pharmaceuticals, Inc. logo
-11.52%
-3.4%
62.32%
49.04%
120.93%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Y-mabs Therapeutics Inc. logo
NA
NA
NA
-0.58
-0.25
-0.12
NA
2.07
Regeneron Pharmaceuticals, Inc. logo
17.85
17.85
1.03
43.09
0.16
0.07
0.01
273.57
Beone Medicines Ltd logo
NA
NA
NA
1.43
-0.19
-0.06
NA
31.22
Vertex Pharmaceuticals Incorporated logo
32.84
NA
1.33
18.07
-0.03
0.13
NA
63.87
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
0.57
-15.01
-0.03
NA
0.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Y-mabs Therapeutics Inc. logo
Buy
$232.5M
-80.02%
NA
-28.22%
Regeneron Pharmaceuticals, Inc. logo
Buy
$74.9B
42.38%
17.85
31.07%
Beone Medicines Ltd logo
NA
$28.5B
68.1%
NA
-16.92%
Vertex Pharmaceuticals Incorporated logo
Buy
$124.1B
121.36%
32.84
-4.86%
Alnylam Pharmaceuticals, Inc. logo
Buy
$31.5B
120.93%
NA
-12.37%

About Y-mabs Therapeutics

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
Organization
Y-mabs Therapeutics
Employees
100
CEO
Mr. Michael Rossi
Industry
Health Technology

Management People of Y-mabs Therapeutics

NameTitle
Mr. Michael Rossi
CEO, President & Director
Mr. Thomas Gad
Founder, Chief Business Officer & Vice Chairman
Mr. Peter P. Pfreundschuh CPA
CFO & Treasurer
Mr. Joris Wiel Jan Wilms
Senior VP & COO
Dr. Torben Lund-Hansen M.Sc., Ph.D.
Senior VP & CTO
Ms. Courtney Dugan
Vice President of Investor Relations
Dr. Vignesh Rajah M.B.A., MBBS
Senior VP & Chief Medical Officer
Dr. Norman D. LaFrance FACNP, FACP, M.D.
Chief Development Officer
Mr. Doug Gentilcore
Senior VP & Head of DANYELZA Business Unit

Important FAQs about investing in YMAB Stock from India :

What is Y-mabs Therapeutics share price today?

Y-mabs Therapeutics share price today stands at $4.85, Open: $4.85 ; Previous Close: $4.96 ; High: $4.98 ; Low: $4.57 ; 52 Week High: $18.19 ; 52 Week Low: $4.85.

The stock opens at $4.85, after a previous close of $4.96. The stock reached a daily high of $4.98 and a low of $4.57, with a 52-week high of $18.19 and a 52-week low of $4.85.

Can Indians buy Y-mabs Therapeutics shares?

Yes, Indians can invest in the Y-mabs Therapeutics (YMAB) from India.

With INDmoney, you can buy Y-mabs Therapeutics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Y-mabs Therapeutics at zero transaction cost.

How can I buy Y-mabs Therapeutics shares from India?

It is very easy to buy Y-mabs Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Y-mabs Therapeutics (YMAB) be purchased?

Yes, you can buy fractional shares of Y-mabs Therapeutics with INDmoney app.

What are the documents required to start investing in Y-mabs Therapeutics stocks?

To start investing in Y-mabs Therapeutics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Y-mabs Therapeutics Stock (YMAB)?

Today’s highest price of Y-mabs Therapeutics (YMAB) is $4.98.

Today’s lowest price of Y-mabs Therapeutics (YMAB) is $4.57.

What is today's market capitalisation of Y-mabs Therapeutics?

Today's market capitalisation of Y-mabs Therapeutics YMAB is 232.5M

What is the 52 Week High and Low Range of Y-mabs Therapeutics Stock (YMAB)?

  • 52 Week High

    $18.19

  • 52 Week Low

    $4.85

What are the historical returns of Y-mabs Therapeutics (YMAB)?

  • 1 Month Returns

    -17.33%

  • 3 Months Returns

    -64.55%

  • 1 Year Returns

    -72.43%

  • 5 Years Returns

    -80.02%

Who is the Chief Executive Officer (CEO) of Y-mabs Therapeutics ?

Mr. Michael Rossi is the current Chief Executive Officer (CEO) of Y-mabs Therapeutics.